Searl gets DRAP approval for biosimilar drug

MG News | December 14, 2023 at 12:06 PM GMT+05:00

Add Mettisglobal as a Trusted Source on Google

0:00

December 14, 2023 (MLN): The Searle Company Limited (PSX: SEARL) has received approval from the Drug Regulatory Authority of Pakistan (DRAP) for ADALIMUMAB, a biosimilar drug developed in collaboration with BioRay Biopharmaceuticals Co. Limited, China, the company's latest filing on the PSX showed today.

This marks the first locally manufactured Monoclonal antibody (mABs) in Pakistan, the notice reads.

The introduction of ADALIMUMAB to the market within the next 3-6 months is a strategic move aimed at providing high-quality, affordable biotechnology medicines to patients in Pakistan, it said.

The company said that this development aligns with its commitment to diversifying its product portfolio, thereby enhancing the quality of earnings and shareholders' value.

Copyright Mettis Link News

Related News

Name	Price/Vol	%Chg/NChg
KSE100	179,571.27 436.67M	1.06% 1878.35
ALLSHR	108,600.94 844.23M	1.00% 1073.54
KSE30	53,548.42 162.02M	0.99% 525.53
KMI30	256,725.70 154.74M	0.76% 1936.43
KMIALLSHR	70,620.69 563.61M	0.98% 683.55
BKTi	48,625.03 36.31M	1.37% 658.39
OGTi	37,179.52 8.29M	0.94% 345.85

Symbol	Bid/Ask	High/Low

Name	Last	High/Low	Chg/%Chg
BITCOIN FUTURES	60,425.00	60,535.00 59,790.00	430.00 0.72%
BRENT CRUDE	73.08	75.13 71.38	-2.18 -2.90%
RICHARDS BAY COAL MONTHLY	103.50	0.00 0.00	0.25 0.24%
ROTTERDAM COAL MONTHLY	113.35	114.25 113.00	-0.05 -0.04%
USD RBD PALM OLEIN	1,135.00	1,135.00 1,135.00	0.00 0.00%
CRUDE OIL - WTI	70.24	71.86 68.56	-1.68 -2.34%
SUGAR #11 WORLD	14.55	14.68 14.02	0.45 3.19%